Ixekizumab provides persistent improvements in health-related quality of life and the sexual impact associated with moderate-to-severe genital psoriasis in adult patients during a 52-week, randomised, placebo-controlled, phase 3 clinical trial.
J Eur Acad Dermatol Venereol
; 36(4): e277-e279, 2022 Apr.
Article
in En
| MEDLINE
| ID: mdl-34812561
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Psoriasis
/
Dermatologic Agents
Type of study:
Clinical_trials
/
Risk_factors_studies
Aspects:
Patient_preference
Limits:
Adult
/
Humans
Language:
En
Journal:
J Eur Acad Dermatol Venereol
Journal subject:
DERMATOLOGIA
/
DOENCAS SEXUALMENTE TRANSMISSIVEIS
Year:
2022
Document type:
Article
Affiliation country:
Ireland
Country of publication:
United kingdom